Drug residues and endocrine disruptors in drinking water: risk for humans?

The presence of pharmaceuticals and endocrine disruptors in the environment raises many questions about risk to the environment and human health. Environmental exposure has been largely studied, providing to date a realistic picture of the degree of contamination of the environment by pharmaceuticals and hormones. Conversely, little information is available regarding human exposure. NSAIDS, carbamazepine, iodinated contrast media, β-blockers, antibiotics have been detected in drinking water, mostly in the range of ng/L. it is questioned if such concentrations may affect human health. Currently, no consensus among the scientific community exists on what risk, if any, pharmaceuticals and endocrine disruptors pose to human health. Future European research will focus, on one hand, on genotoxic and cytotoxic anti-cancer drugs and, on the other hand, on the induction of genetic resistance by antibiotics. This review does not aim to give a comprehensive overview of human health risk of drug residues and endocrine disruptors in drinking water but rather highlight important topics of discussion.

[1]  D. Larsson,et al.  Variations in bioconcentration of human pharmaceuticals from sewage effluents into fish blood plasma. , 2007, Environmental toxicology and pharmacology.

[2]  G. Massmann,et al.  Field Studies on the Fate and Transport of Pharmaceutical Residues in Bank Filtration , 2004 .

[3]  T. Ternes,et al.  Pharmaceuticals and personal care products in the environment: agents of subtle change? , 1999, Environmental health perspectives.

[4]  J. Sumpter.  Environmental Effects of Human Pharmaceuticals , 2007 .

[5]  Klaus Kümmerer,et al.  Pharmaceuticals in the environment : sources, fate, effects and risks , 2008 .

[6]  T. Poiger,et al.  Occurrence and fate of the cytostatic drugs cyclophosphamide and ifosfamide in wastewater and surface waters. , 2006, Environmental science & technology.

[7]  Emmanuelle Vulliet,et al.  Occurrence of pharmaceuticals and hormones in drinking water treated from surface waters , 2011 .

[8]  R. Stillman.  In utero exposure to diethylstilbestrol: adverse effects on the reproductive tract and reproductive performance and male and female offspring. , 1982, American journal of obstetrics and gynecology.

[9]  T. Backhaus,et al.  On the Ecotoxicology of Pharmaceutical Mixtures , 2008 .

[10]  G. Aherne,et al.  The relevance of the presence of certain synthetic steroids in the aquatic environment , 1989, The Journal of pharmacy and pharmacology.

[11]  Andrew C Johnson,et al.  Cytotoxic drugs in drinking water: A prediction and risk assessment exercise for the thames catchment in the United Kingdom , 2009, Environmental toxicology and chemistry.

[12]  Andreas Kortenkamp,et al.  Do cytotoxic chemotherapy drugs discharged into rivers pose a risk to the environment and human health? An overview and UK case study , 2008 .

[13]  T. Backhaus,et al.  Low-Level Exposure to Multiple Chemicals: Reason for Human Health Concerns? , 2007, Environmental health perspectives.

[14]  Karen A Kidd,et al.  Collapse of a fish population after exposure to a synthetic estrogen , 2007, Proceedings of the National Academy of Sciences.

[15]  J. Pawliszyn,et al.  Tissue-specific in vivo bioconcentration of pharmaceuticals in rainbow trout (Oncorhynchus mykiss) using space-resolved solid-phase microextraction. , 2010, Environmental science & technology.

[16]  A. Collier.  Pharmaceutical Contaminants in Potable Water: Potential Concerns for Pregnant Women and Children , 2007, EcoHealth.

[17]  M. Mcmaster,et al.  Bioaccumulation of the pharmaceutical 17alpha-ethinylestradiol in shorthead redhorse suckers (Moxostoma macrolepidotum) from the St. Clair River, Canada. , 2010, Environmental pollution.

[18]  Thomas Steger-Hartmann,et al.  Biodegradability of the anti-tumour agent ifosfamide and its occurrence in hospital effluents and communal sewage , 1997 .

[19]  U. Dünnbier,et al.  Identification and significance of phenazone drugs and their metabolites in ground- and drinking water. , 2002, Chemosphere.

[20]  S. Gapstur,et al.  Cancer Epidemiology and Prevention, 3rd Edition , 2007 .

[21]  D. Barceló,et al.  Fate and occurrence of X-ray contrast media in the environment , 2007, Analytical and bioanalytical chemistry.

[22]  Joel P Bercu,et al.  Human health risk assessments for three neuropharmaceutical compounds in surface waters. , 2008, Regulatory toxicology and pharmacology : RTP.

[23]  J. Fraumeni,et al.  Cancer epidemiology and prevention. , 2006 .

[24]  A. V. van Wezel,et al.  Toxicological relevance of emerging contaminants for drinking water quality. , 2010, Water research.

[25]  Mats Tysklind,et al.  Therapeutic levels of levonorgestrel detected in blood plasma of fish: results from screening rainbow trout exposed to treated sewage effluents. , 2010, Environmental science & technology.

[26]  J. Sumpter,et al.  Effects of the synthetic estrogen 17α‐ethinylestradiol on the life‐cycle of the fathead minnow (Pimephales promelas) , 2001 .

[27]  S. Jørgensen,et al.  Occurrence, fate and effects of pharmaceutical substances in the environment--a review. , 1998, Chemosphere.

[28]  Klaus Kümmerer,et al.  The presence of pharmaceuticals in the environment due to human use--present knowledge and future challenges. , 2009, Journal of environmental management.

[29]  J. Garric,et al.  Progestagens for human use, exposure and hazard assessment for the aquatic environment. , 2009, Environmental pollution.

[30]  V. Cunningham,et al.  Human health risk assessment from the presence of human pharmaceuticals in the aquatic environment. , 2009, Regulatory toxicology and pharmacology : RTP.

[31]  Xiu-Sheng Miao,et al.  The human lipid regulator, gemfibrozil bioconcentrates and reduces testosterone in the goldfish, Carassius auratus. , 2005, Aquatic toxicology.

[32]  B. Roig,et al.  The chick embryo: an animal model for detection of the effects of hormonal compounds , 2007, Analytical and bioanalytical chemistry.

[33]  D. DeMarini,et al.  Occurrence, genotoxicity, and carcinogenicity of regulated and emerging disinfection by-products in drinking water: a review and roadmap for research. , 2007, Mutation research.

[34]  Benjamin D. Stanford,et al.  Pharmaceuticals and endocrine disrupting compounds in U.S. drinking water. , 2009, Environmental science & technology.

[35]  Benoit Roig.  Pharmaceuticals in the Environment: Current knowledge and need assessment to reduce presence and impact , 2010 .

[36]  C. Metcalfe,et al.  Uptake and depuration of the anti-depressant fluoxetine by the Japanese medaka (Oryzias latipes). , 2008, Chemosphere.

[37]  J. Schwaiger,et al.  Toxic effects of the non-steroidal anti-inflammatory drug diclofenac. Part I: histopathological alterations and bioaccumulation in rainbow trout. , 2004, Aquatic toxicology.

[38]  V. D'Aco,et al.  Human health risk assessment of carbamazepine in surface waters of North America and Europe. , 2010, Regulatory toxicology and pharmacology : RTP.

[39]  Aleem Ahmed Khan,et al.  Diclofenac residues as the cause of vulture population decline in Pakistan , 2004, Nature.

[40]  T. Backhaus,et al.  Predictability of the toxicity of a multiple mixture of dissimilarly acting chemicals to Vibrio fischeri , 2000 .

[41]  Backhaus,et al.  The single substance and mixture toxicity of quinolones to the bioluminescent bacterium Vibrio fischeri. , 2000, Aquatic toxicology.

[42]  O. Thomas,et al.  Occurrence and fate of pharmaceutical products and by-products, from resource to drinking water. , 2009, Environment international.

[43]  T. Steger-Hartmann,et al.  Biological degradation of cyclophosphamide and its occurrence in sewage water. , 1997, Ecotoxicology and environmental safety.

[44]  K. Thomas,et al.  Environmental assessment of Norwegian priority pharmaceuticals based on the EMEA guideline. , 2008, Ecotoxicology and environmental safety.